KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Change in Inventory (2016 - 2025)

Emergent BioSolutions' Change in Inventory history spans 16 years, with the latest figure at -$14.2 million for Q4 2025.

  • For Q4 2025, Change in Inventory fell 29.09% year-over-year to -$14.2 million; the TTM value through Dec 2025 reached $30.3 million, up 23.67%, while the annual FY2025 figure was $30.3 million, 23.67% up from the prior year.
  • Change in Inventory reached -$14.2 million in Q4 2025 per EBS's latest filing, down from $17.6 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $99.9 million in Q1 2021 to a low of -$127.7 million in Q4 2022.
  • Average Change in Inventory over 5 years is $4.8 million, with a median of $6.6 million recorded in 2021.
  • Peak YoY movement for Change in Inventory: crashed 1584.88% in 2022, then soared 17900.0% in 2024.
  • A 5-year view of Change in Inventory shows it stood at $8.6 million in 2021, then plummeted by 1584.88% to -$127.7 million in 2022, then skyrocketed by 79.95% to -$25.6 million in 2023, then surged by 57.03% to -$11.0 million in 2024, then decreased by 29.09% to -$14.2 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Change in Inventory are -$14.2 million (Q4 2025), $17.6 million (Q3 2025), and $24.7 million (Q2 2025).